Abstract
• Established and emerging liquid embolic agents were summarized in this review. • The embolization mechanism and usage of liquid embolic agents were discussed. • Prospective and rational design guidelines were discussed. Minimally invasive interventional embolization has tremendous advantages over conventional surgery in the treatment of vascular diseases and malignant tumors. Particularly, liquid embolic agents have garnered much attention owing to their properties of deep vascular penetration and full occlusion of vasculature independent of thrombus formation, which relies on the patient's coagulation system. Despite their drawbacks, traditional liquid embolic agents, such as lipiodol, N -butyl-2-cyanoacrylate, and Onyx, have benefited numerous patients. The original liquid embolic agents have been modified and optimized, and novel liquid embolic agents have also been developed using different strategies and mechanisms. This minireview provides a brief overview of liquid embolic agents, including approved and potential ones. Challenges, prospects, and rational design guidelines are also discussed. This review may spark interest in liquid embolic agents and open new avenues for the smart design of improved embolic agents in the development of personalized and precision medicine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
